Treatment of non-small cell lung cancer patients with performance status2 (PS2)

被引：9
作者：
Boukovinas, Ioannis [1 ]
Kosmidis, Paris [2 ]
机构：
[1] Theagenion Krankenhauses, Dept Med Oncol 2, Thessaloniki 54007, Greece
[2] Hygeia Hosp, Dept Med Oncol 2, Athens, Greece
来源：
LUNG CANCER | 2009年 / 63卷 / 01期
关键词：
Non-small cell lung cancer; Performance status2 (PS2); Chemotherapy; Treatment; Toxicity profile; Prognostic factor; PHASE-II TRIAL; PACLITAXEL PLUS CARBOPLATIN; COOPERATIVE-ONCOLOGY-GROUP; PROGNOSTIC-FACTORS; GEMCITABINE PLUS; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; SUPPORTIVE CARE; CISPLATIN; SURVIVAL;
D O I：
10.1016/j.lungcan.2008.05.016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Performance status2 (PS2) patients represent a significant proportion of the advanced non-small cell lung cancer (NSCLC) population who in the large part have been under-represented in clinical trials. The optimal treatment regimen for this group of patients is still under debate mainly because their enrollment either in trials of first-line treatment for advanced disease is practically non-existent or limited at the very best. The emphasis in these patients' care should be on maintenance and improvement of quality of life (QOL) with treatment strategies that provide rapid clinical improvement. On the basis of current evidence, chemotherapy appears justified to patients with advanced NSCLC and a PS of 2. The choice of the drug should be based on the toxicity profile of each agent and type of co-morbid conditions. Additional studies are needed in order to evaluate the future perspectives of the molecular targeted agents in the treatment of PS2 patients. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：10 / 15
页数：6
相关论文
共 50 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]   Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer:: A Spanish lung cancer group phase III randomized trial [J].
Alberola, V ;
Camps, C ;
Provencio, M ;
Isla, D ;
Rosell, R ;
Vadell, C ;
Bover, I ;
Ruiz-Casado, A ;
Azagra, P ;
Jiménez, U ;
González-Larriba, JL ;
Diz, P ;
Cardenal, F ;
Artal, A ;
Carrato, A ;
Morales, S ;
Sánchez, JJ ;
de las Peñas, R ;
Felip, E ;
López-Vivanco, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3207-3213
[3]   Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].
Anderson, H. ;
Hopwood, P. ;
Stephens, R. J. ;
Thatcher, N. ;
Cottier, B. ;
Nicholson, M. ;
Milroy, R. ;
Maughan, T. S. ;
Falk, S. J. ;
Bond, M. G. ;
Burt, P. A. ;
Connolly, C. K. ;
McIllmurray, M. B. ;
Carmichael, J. .
BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453
[4]   Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer [J].
Ando, M ;
Ando, Y ;
Sugiura, S ;
Minami, H ;
Saka, H ;
Sakai, S ;
Shimokata, K ;
Hasegawa, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (02) :249-253
[5]   Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer [J].
Argiris, A ;
Mittal, N .
LUNG CANCER, 2004, 43 (03) :317-322
[6]   CANCER STATISTICS, 1993 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (01) :7-26
[7]   Prognostic factors in non-small cell lung cancer - A decade of progress [J].
Brundage, MD ;
Davies, D ;
Mackillop, WJ .
CHEST, 2002, 122 (03) :1037-1057
[8]   Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution [J].
Buccheri, G ;
Ferrigno, D ;
Tamburini, M .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (07) :1135-1141
[9]  
CRINO L, 2002, P AN M AM SOC CLIN, V21, P315
[10]   Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life [J].
Cullen, MH ;
Billingham, LJ ;
Woodroffe, CM ;
Chetiyawardana, AD ;
Gower, NH ;
Joshi, R ;
Ferry, DR ;
Rudd, RM ;
Spiro, SG ;
Cook, JE ;
Trask, C ;
Bessell, E ;
Connolly, CK ;
Tobias, J ;
Souhami, RL .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3188-3194
12345